Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic

  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cassava Sciences Inc (NQ: SAVA )

4.620 -21.860 (-82.55%)
Streaming Delayed Price Updated: 2:39 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cassava Sciences Inc

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
33 34 Next >
Benzinga's Daily Brief On Trending Tickers For Feb. 11, 2022: Cassava Sciences, Cleveland Cliffs, GameStop, and More
Benzinga’s “Daily Brief On Trending Tickers” highlights top-searched tickers from around the web and uses the Benzinga Pro platform to highlight recent news... 
Via Benzinga
$1000 Invested In This Stock 5 Years Ago, Would Be Worth This Much
Cassava Sciences (NASDAQ:SAVA) has outperformed the market over the past 5 years by 53.42% on an annualized basis. 
Via Benzinga
Cassava Sciences Whale Trades Spotted
Someone with a lot of money to spend has taken a bullish stance on Cassava Sciences (NASDAQ:SAVA). And retail traders should know. We noticed this today when the big position showed up on publicly... 
Via Benzinga
Does Cassava Sciences and Its Alzheimer’s Drug Really Have What It Takes?
Can Cassava Sciences' Simufilam drug really treat Alzheimer's? Who really knows. SAVA stock is pure speculation either way. 
Via InvestorPlace
Keep an Eye on $60 as a Target Price for Cassava Sciences
As long as you're using a moderate position size, it's fine to hold SAVA stock as it has a tendency to move fast and far from time to time. 
Via InvestorPlace
This Is What Whales Are Betting On Cassava Sciences
Someone with a lot of money to spend has taken a bearish stance on Cassava Sciences (NASDAQ:SAVA). And retail traders should know. We noticed this today when the big position showed up on publicly... 
Via Benzinga
5 Short Squeeze Candidates To Watch: Vinco Ventures, TSR Inc, Biofrontera And More
Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.... 
Via Benzinga
The End Result May Be Worth the Wait With Cassava Sciences Stock
SAVA stock will continue to trade sideways until the moment of truth arrives for its drug candidate Simufilam. 
Via InvestorPlace
Short Squeeze Activity: New Players, Same Game, Different Results
Short squeezes will remain a big story in the financial news media until heavily shorted stocks that have been pushed up by individual investors come crashing back to earth. 
Via Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
Cassava Sciences Is an Exciting Roll-the-Dice Biotech Trade
Take a wild ride -- but keep your position size small, please -- as SAVA stock could return to all-time highs or plummet to new depths soon. 
Via InvestorPlace
Top Ideas in the Small Cap Biotech Space (LEXTF, ABBV, SAVA, SNDL, RETA, PAHC)
Via AB Newswire
Canadian Biotech Disruptor Lexston Life Sciences is unlocking the God Molecule (LEXTF, ICPT, AKBA, QURE, BNTX, SAVA)
Via AB Newswire
Topics Bonds Stocks
Exposures Debt Markets US Equities
Cassava Sciences Stock Is Still Risky but Has Plenty of Upside Potential
Among the plethora of high-risk, speculative, clinical-stage biotech plays out there, SAVA stock is one of the better bets out there. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our... 
Via Benzinga
Peering Into Cassava Sciences Inc's Recent Short Interest
Cassava Sciences Inc's (NASDAQ:SAVA) short percent of float has risen 22.31% since last its last report. The company recently reported that it has 10.25 million shares sold short... 
Via Benzinga
Cassava Sciences Stock Is Worth Almost 4x More After Adjusting for Risk
Cassava Sciences stands to gain using probability methods. On a risk-adjusted basis, SAVA stock is worth 3.7 times more, despite its downside. 
Via InvestorPlace
7 High Risk Stocks That Are Worth The Volatile Vibes
These seven high risk stocks made wild moves in 2021, but still have the potential to rocket higher. All are full of both risk and reward. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our... 
Via Benzinga
Global Alzheimer’s Disease Therapeutics Market Projected To Generate Revenue Of $9.97 Billion By 2028
Palm Beach, FL –January 4, 2022 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease is a degenerative, progressive ailment that attacks the brain’s nerve cells, resulting in memory loss,... 
Via FinancialNewsMedia
Exposures COVID-19
How Are The Shorts Feeling About Cassava Sciences Inc?
Cassava Sciences Inc's (NASDAQ:SAVA) short interest has increased 22% since the last report. The company recently reported that it has 10 million shares sold short, which is... 
Via Benzinga
7 of the Best Meme Stocks for 2022 to Buy Now
Although the meme stocks phenomenon is sagging in popularity, these seven current and/or former Reddit favorites could make another "to the moon" move or two in 2022. 
Via InvestorPlace
Cassava Sciences Whale Trades Spotted
A whale with a lot of money to spend has taken a noticeably bearish stance on Cassava Sciences. Looking at options history for Cassava Sciences (NASDAQ:SAVA) we detected 12... 
Via Benzinga
Investing In This Alzheimer’s Drug Maker Risky But Could Be Quite Rewarding
Coming up with the medicine for Alzheimer's Disease can be really good for a company and although it might seem risky, with great risks come great rewards. 
Via Talk Markets
(SAVA) - Analyzing Cassava Sciences Inc's Short Interest
Cassava Sciences Inc's (NASDAQ:SAVA) short percent of float has fallen 26.17% since last its last report. The company recently reported that it has 8.38 million shares sold short... 
Via Benzinga
NAKD Stock: Is the Naked Brand Reverse Stock Split Good or Bad? What Investors Are Saying
Naked Brand (NAKD) stock is in the news today as investors react to the company's 15-for-one reverse stock split for Tuesday. 
Via InvestorPlace
Here's How Much $1000 Invested In Cassava Sciences 5 Years Ago Would Be Worth Today
Cassava Sciences (NASDAQ:SAVA) has outperformed the market over the past 5 years by 41.64% on an annualized basis. Buying $1,000 In SAVA: 5 years ago, an investor could have... 
Via Benzinga
SAVA Stock Alert: What Is Going on With Red-Hot Cassava Sciences Today?
Biotech company Cassava saw a big jump today on positive news related to its Alzheimer's disease treatment. Keep an eye on SAVA stock. 
Via InvestorPlace
55 Biggest Movers From Yesterday
Gainers Reliance Global Group, Inc. (NASDAQ: RELI) shares jumped 78.7% to close at $5.45 on Tuesday after gaining around 6% on Monday. Biofrontera Inc. (NASDAQ: BFRI) gained 44.8... 
Via Benzinga
Science Journal Finds No Evidence To Data Manipulation By Cassava Sciences' In 2005 Publication
Cassava Sciences Inc (NASDAQ: SAVA) has been informed by the Neuroscience journal that there is no evidence to support claims of data manipulation in a 2005 paper authored by... 
Via Benzinga
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
33 34 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.